Member Info for MRK2020

I don't post much any more here, but remain invested. It's my view that the SP has reached the bottom, with clear support around these levels. There is decent potential going forward. As such I won't be selling anytime soon; it will take time for that potential to be reached.
GLA

Ohmni...if you and JJ are in Vast, then it seems you're as likely to pick a bad stock as me (and a good one here of course)..
Though in both cases patience is key...

RE $4..Nothing a share consolidation couldn't address.

Jimjam...I see you are in TRX also...I think there maybe parallels here with the lack of sentiment, and poor communications there based on the placing but the fundamentals being sound. Presented a great buy in opportunity there.

Could well be...
meanwhile, I am content with the consolidation period going on at the moment. No news gives VAST no opportunity to show off their underwhelming use of language and grasp of market sentiment. Something that they can easily improve on I might add. It did amuse me when AntHarry (I think) and others wrote dummy RNS's to show them how they should have/could have worded them.
Anyhow, quiet news period, while ramping up production (no news should mean that is going to plan?!) and addressing some of the other long-standing issues re finance etc; all suits me fine. And should improve sentiment and SP - but as ever, we shall see.

I meant re diamonds in past 9 months.. Plenty has happened in Romania and in the board rooms of banks

Welcome Reaper.
We can only speculate on whether atlas had any say in shares vs cash, but certainly true that if they did it is a good sign. Loving the photo of AP and JC from Botswana Diamonds however.. Again a sign of something going on, which is more than we have had in the past 9 months since I bought in. You may well have timed your Vast foray well. I thought I had though ha. GLA

My take on it is that this is fantastic... They have stated the plan previously, that being that if foralumab P2 results indicate a follow on study then they will need further capital to advance their pipeline. Well I think we have a smoking gun here. The at the market sales shows the confidence further.. As in they do not anticipate needed to offer a discounted placing to raise funds. The only slight frustration was that the application notes 1st quarter 2021 for results of Brazil but we know they are imminent.
Ps I agree that next trial likely to be P2 and P3 combined.

I tried to join the fireside chat, but frankly was put off by the level of detail wanted to join.
Anyhow, given that it was chiefly an oncology event, could anyone confirm what was said regarding this area?
I have seen the tweet that "Results from the cancer work that $TLSA has been doing are absolutely amazing" - but what results are these - anyone have further details?
I assume Milciclib and not Stemprinter (but could be both)
I note the Phase 2 study in Sorafenib-resistant HCC for Milciclib results from the recent investor presentation
(Stabilized Disease (SD): 61%, Clinical Benefit Response: 64%). NB Phase 2b trial starting in Autumn in HCC patients in combination with a TKI (Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy. TKIs come as pills, taken orally. A targeted therapy identifies and attacks specific types of cancer cells while causing less damage to normal cells.)
https://ir.tizianalifesciences.com/presentation

Wowser... I do believe this qualifies as the unambiguous, unadulterated, positive update that was so clearly needed. I am pleasantly surprised. Keep them coming.

So the proactive article cites a Wainwright (broker) target reiteration of $11..https://www.proactiveinvestors.com/companies/amp/news/938836

I was reading that thinking that's great, but that could well be years away.
then voila...the article confirms this is merely the 12 month target..

some of the adjectives used are noteworthy..
"heavy hitting" (new CMO)
"blockbuster" products (monoclonal antibodies)
"game-changer"...the oral nasal administrations patented by TILS [it's a pretty big game we are talking about here]
"world class" business...

And there we have ,in bite size, the reasons why we are invested.
Truly exciting.

What this share needs is a bit of unadulterated, unambiguous, good news. With no ifs, buts, maybes.
As many will appreciate there has been some very good developments of late, Jorc, production, sales of copper, etc.. Yet somehow..none of those managed to meet the above criteria. So, come along AP and Co, and share some of the good stuff. Many thanks. Ps news of sales would count and build a lot of confidence. Just ask the ODX gang!

I think we know enough to merit follow on trial/s, ramping up the cohort sizes ...which are the next step. I am sure that they are well on the way towards planning these as proposed in the recent REDCAP investor teleconferences.

Generally making rather than losing money...which would be a huge milestone. Look around AIM there are hundreds of companies that don't make money (and many never will!)
Unfortunately the forward guidance is not available due to Covid-19 uncertainties, but 2022 was the expected break-even point. The uncertainty will have held back the SP a little, and the trading update will be enlightening.

“The global regenerative medicine market was valued at $5.444Bn in 2016, and is estimated to reach $39.325Bn
by 2023" cited in the 2018 annual report..

Andy - yes can be a quiet board...pros and cons of course but idiot free so I am content enough.
Broadly speaking this is an important time for the company, as we move towards profitability in the 18 months or so.
That's the element I find particularly attractive... a major inflection point and pretty exciting to be involved with.
The SP was hit hard by a significantly discounted placement back in May 2020, but the money was needed to support expansion of production capacity. Although Covid-19 will have impacted on elective procedures, the expansion work over the next 6 months or so, will provide far more capacity going forward (up to $36 million extra sales per year). Demand has not been the issue here in the past (as the products are world class)- it is supply that has held TRX back. Hopefully we now have Phase 1 of the expansion programme online. We hope to find out more later this month in the anticipated company update.

Each US share is equivalent to 2 UK shares so not quite smashing it..~30% lower value in fact.
...but made me look :-)

yes..that's my take on it too; plus possible board changes. But as ever, it's as clear as mud. Personally I think the least we deserved was the detail of what the fook actually occurred.

New RNS re a director purchase. That is encouraging, even if smallish.

So...we should hear about phase 1 expansion this month. It was scheduled to complete last month. Would be great to hear if it is up and running. some statements from the Harman report..
'...Phase 1 to add two new clean rooms at a cost of $1.3m and take six months - enough extra capacity to break even.
Phase 2 adds up to 10 clean rooms at a cost of $4.5m-$5.5m and will take ca.12 months
Expansion completion has potential to add up to $36m p.a. to sales.'

Our current market cap less than 40million.

Worth considering those last two sentences in unison.

In my view there will be a backlog of operations from Covid so a good time to be expanding ready to increase supply, when times are better post vaccines..(fingers crossed)
a good hold here IMO while we await news later this month

I'm just taking on the 'no adverse events' message in the RNS. Now, let's consider this more closely. While we don't know the definition of adverse events, it is likely to include suspected drug reactions, deaths, and potentially worsened state, e.g. requiring ventilation..(also an outcome of the Sng trial). Anyhow, hopefully there is a broad adverse event definition in use and we are looking at a treatment that has indications of efficacy even at this early stage. Truly exciting month.
One point of disappointment is that I expected a recruitment of 60, and we are some way off of that which isn't helpful in the understanding of dose etc and the planning of the follow on trial/s. Can't wait for more news on the results and forward plans.